CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Preferred Stock [Member] Series A convertible preferred stock [Member]	Preferred Stock [Member] Series A-1 convertible preferred stock [Member]	Preferred Stock [Member] Series B convertible preferred stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2023		$ 47,458	$ 4,132	$ 59,855
Beginning balance, Shares at Dec. 31, 2023		2,286,873	312,094	2,625,896
Beginning balance, Shares at Dec. 31, 2023					359,569
Beginning balance at Dec. 31, 2023	$ (182,921)				$ 1	$ 4,159	$ (187,081)
Conversion of convertible preferred stock to common stock in connection with the Merge, Share		(2,286,873)	(312,094)	(2,625,896)	5,224,863
Conversion of convertible preferred stock to common stock in connection with the Merger, Value	111,445	$ (47,458)	$ (4,132)	$ (59,855)	$ 1	111,444
Issuance of common stock in the pre-closing financing, Shares					1,682,045
Issuance of common stock in the pre-closing financing, Value	42,000					42,000
Issuance of common stock for conversion of convertible notes, Shares					1,433,410
Issuance of common stock for conversion of Convertible Notes, Value	22,705					22,705
Issuance of common stock to Homology shareholders in reverse recapitalization, Shares					3,229,633
Issuance of common stock to Homology shareholders in reverse recapitalization, Value	64,292					64,292
Reverse recapitalization transaction costs	(10,013)					(10,013)
Issuance of CVR at fair value	(180)					(180)
Issuance of common stock from option exercises, Shares					255,486
Issuance of common stock to Amgen	0
Issuance of common stock from option exercises	1,694					1,694
Issuance Of Common Stocks From Rsu Vesting, Shares					12,609
Stock-based compensation expense	4,386					4,386
Other comprehensive loss	0
Net Income (Loss)	(47,733)						(47,733)
Ending balance, Shares at Dec. 31, 2024		0	0	0
Ending balance at Dec. 31, 2024		$ 0	$ 0	$ 0	$ 2
Ending balance, Shares at Dec. 31, 2024					12,197,615
Ending balance at Dec. 31, 2024	5,675					240,487	(234,814)
Issuance of common stock to Amgen, Shares					553,695
Issuance of common stock to Amgen	1,263					1,263
Issuance Of Common Stocks From Rsu Vesting, Shares					106,737
Stock-based compensation expense	5,255					5,255
Other comprehensive loss	0
Net Income (Loss)	29,821						29,821
Ending balance, Shares at Dec. 31, 2025		0	0	0
Ending balance at Dec. 31, 2025		$ 0	$ 0	$ 0
Ending balance, Shares at Dec. 31, 2025					12,858,047
Ending balance at Dec. 31, 2025	$ 42,014				$ 2	$ 247,005	$ (204,993)